Literature DB >> 12351381

Adhesion of synchronized human hematopoietic progenitor cells to fibronectin and vascular cell adhesion molecule-1 fluctuates reversibly during cell cycle transit in ex vivo culture.

Sandra Huygen1, Olivier Giet, Vincent Artisien, Ivano Di Stefano, Yves Beguin, André Gothot.   

Abstract

Ex vivo expansion of hematopoietic stem/progenitor cells may result in defective engraftment. Human cord blood CD34(+) progenitor cells were synchronized and assayed for adhesion and migration onto fibronectin (Fn) and vascular cell adhesion molecule-1 (VCAM-1) at different stages of a first cell cycle executed ex vivo. During S phase transit, adhesion to Fn was transiently increased while binding to VCAM-1 was reversibly decreased, after which adhesion to both ligands returned to baseline levels with cell cycle completion. Transmigration across Fn and VCAM-1 decreased irreversibly during S phase progression. The function of alpha4 and alpha5 integrins was assessed with specific neutralizing antibodies. In uncultured CD34(+) cells and long-term culture-initiating cells (LTC-ICs), both adhesion and migration on Fn were inhibited by anti-alpha4 but not by anti-alpha5 antibodies. In mitotically activated CD34(+) cells and LTC-ICs, adhesion and migration on Fn were mainly dependent on alpha5 integrin and to a lesser extent on alpha4 integrin. Changes in integrin function were not dependent on parallel modulation of integrin expression. In conclusion, Fn and VCAM-1 binding of progenitor cells fluctuates reversibly during cell cycle transit ex vivo. In addition, our data show that mitogenic activation induces a shift from a dominant alpha4 to a preferential alpha5 integrin-dependent interaction with Fn.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12351381     DOI: 10.1182/blood.V100.8.2744

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

1.  Pharmacological inhibition of EGFR signaling enhances G-CSF-induced hematopoietic stem cell mobilization.

Authors:  Marnie A Ryan; Kalpana J Nattamai; Ellen Xing; David Schleimer; Deidre Daria; Amitava Sengupta; Anja Köhler; Wei Liu; Matthias Gunzer; Michael Jansen; Nancy Ratner; Timothy D Le Cras; Amanda Waterstrat; Gary Van Zant; Jose A Cancelas; Yi Zheng; Hartmut Geiger
Journal:  Nat Med       Date:  2010-09-26       Impact factor: 53.440

2.  Ex vivo expansion of hematopoietic progenitor cells is associated with downregulation of alpha4 integrin- and CXCR4-mediated engraftment in NOD/SCID beta2-microglobulin-null mice.

Authors:  Jacques Foguenne; Ivano Di Stefano; Olivier Giet; Yves Beguin; André Gothot
Journal:  Haematologica       Date:  2009-01-14       Impact factor: 9.941

3.  High-resolution video monitoring of hematopoietic stem cells cultured in single-cell arrays identifies new features of self-renewal.

Authors:  Brad Dykstra; John Ramunas; David Kent; Lindsay McCaffrey; Erin Szumsky; Liam Kelly; Kristen Farn; April Blaylock; Connie Eaves; Eric Jervis
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-15       Impact factor: 11.205

4.  Functional nanofiber scaffolds with different spacers modulate adhesion and expansion of cryopreserved umbilical cord blood hematopoietic stem/progenitor cells.

Authors:  Kian-Ngiap Chua; Chou Chai; Peng-Chou Lee; Seeram Ramakrishna; Kam W Leong; Hai-Quan Mao
Journal:  Exp Hematol       Date:  2007-05       Impact factor: 3.084

5.  Ontological differences in first compared to third trimester human fetal placental chorionic stem cells.

Authors:  Gemma N Jones; Dafni Moschidou; Tamara-Isabel Puga-Iglesias; Katarzyna Kuleszewicz; Maximilien Vanleene; Sandra J Shefelbine; George Bou-Gharios; Nicholas M Fisk; Anna L David; Paolo De Coppi; Pascale V Guillot
Journal:  PLoS One       Date:  2012-09-04       Impact factor: 3.240

6.  Imatinib and nilotinib inhibit hematopoietic progenitor cell growth, but do not prevent adhesion, migration and engraftment of human cord blood CD34+ cells.

Authors:  Ludovic Belle; France Bruck; Jacques Foguenne; André Gothot; Yves Beguin; Frédéric Baron; Alexandra Briquet
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.